Company: BIVIW
Filing Date: 2025-08-04
Form Type: S-1/A
Source: 0001520138-25-000235
Chunk: 107

Company: BIOVIE INC.
Filing Date: 2025-08-04
Form: S-1/A
Chunk 107
---
, and approximately $8.8 million from the AD pivotal Phase 3 clinical study that completed on
December 31, 2023.

The following summarizes the expenses incurred
during the fiscal years ending June 30, 2024 and 2023 for new developmental studies and the completed studies:

| New Development                        |     | 2024 |           |     | 2023 |            |     | Increase   
 (Decrease) |             |   |
|:---------------------------------------|:----|:-----|----------:|:----|:-----|-----------:|:----|:-----------|------------:|:--|
| Sunrise PD Phase 2                     |     | $    |   181,000 |     | $    |          - |     | $          |     181,000 |   |
| Long Covid Program                     |     |      |   106,000 |     |      |          - |     |            |     106,000 |   |
| Sunrise 1 PD PH2b (On hold)            |     |      |   822,000 |     |      |    600,000 |     |            |     222,000 |   |
| Radiance 1 AD MCI-301 Ph2b/3 (On hold) |     |      |   778,000 |     |      |    451,000 |     |            |     327,000 |   |
|                                        |     | $    | 1,887,000 |     | $    |  1,051,000 |     | $          |     836,000 |   |
| Completed Studies                      |     |      |           |     |      |            |     |            |             |   |
| Ascites BIV201 Phase 2b                |     | $    |   672,000 |     | $    |  3,377,000 |     | $          |  (2,705,000 | ) |
| AD mild to moderate pivotal Phase 3    |     |      | 7,888,000 |     |      | 16,630,000 |     |            |  (8,742,000 | ) |
| PD Phase 2                             |     |      |   612,000 |     |      |  2,747,000 |     |            |  (2,135,000 | ) |
| Investig